-
Efficacy of Darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies Littlewood TJ, Kallich JD, San Miguel JF, Hendricks L, Hedenus M Journal of Pain and Symptom Management 31(4):317-25 FI: 2.423 (Q1) Grupo Español de Mieloma. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients Pérez-Simón JA, Sureda A, Fernández-Avilés F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosinol L, Lahuerta J, Diez-Martín JL, León A, García A, Vázquez L, Caballero D, San Miguel JF Leukemia 20(3):542-5 FI: 8.296 (Q1) In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Catley LP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC British Journal of Haematology 134(1):37-44 FI: 4.597 (Q1) International Myeloma Working Group. International uniform response criteria for multiple myeloma Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV Leukemia 20(9):1467-73 FI: 8.296 (Q1) Management of multiple myeloma with Bortezomib: experts review the data and debate the issues Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel JF, Sonneveld P Oncology 70(6):474-82 FI: 2.112 (Q3) Medium term results of percutaneous vertebroplasty in multiple myeloma Ramos L, de Las Heras JA, Sánchez S, González-Porras JR, González R, Mateos MV, San Miguel JF European Journal of Haematology 77(1):7-13 FI: 2.345 (Q3) Pegylated liposomal doxorubicin, melphaln and prednisone therapy for elderly patients with multiple myeloma García-Sanz R, Hernández JM, Sureda A, García-Laraña J, Prósper F, Alegre A, Bárez A, Mateos MV, San Miguel JF Hematological Oncology 24(4):205-11 FI: 1.869 (Q3) Perspective on the current use of bortezomib in multiple myeloma San Miguel JF, Bladé J Haematologica 91(7):871-2 FI: 6.416 (Q1) Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM Bone Marrow Transplantation 37(12):1135-41 FI: 2.998 (Q2) Remarkable activity of novel agents bortezomib and thalidomide in patients non responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM Blood 107(8):3415-6. FI: 10.555 (Q1)
|
